Haemonetics (HAE) News Today

Shares of Haemonetics Co. (NYSE:HAE - Get Free Report) have earned an average recommendation of "Moderate Buy" from the four research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and three have given a buy rating to th

Edgestream Partners L.P. acquired a new stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 20,187 shares of the medical instruments supplier's sto

Westfield Capital Management Co. LP decreased its position in Haemonetics Co. (NYSE:HAE - Free Report) by 1.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 699,861 shares of the medical instruments

Haemonetics Co. (NYSE:HAE - Get Free Report) EVP Anila Lingamneni sold 2,136 shares of the business's stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total transaction of $192,240.00. Following the sale, the executive vice president now directly owns 21,410 shares in the company, valued at $1,926,900. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Quantbot Technologies LP boosted its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 2,101.6% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,068 shares of the medical instruments supplier's stock after acquiring

Allspring Global Investments Holdings LLC grew its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 132.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 502,993 shares of the medical instruments supplier's stock after

Shares of Haemonetics Co. (NYSE:HAE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the four brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and three have given a buy recommendation to the compa

Goldman Sachs Group Inc. boosted its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 14.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 191,253 shares of the medical instruments supplier's stock after

Vanguard Group Inc. raised its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 0.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,406,309 shares of the medical instruments supplie

Wellington Management Group LLP boosted its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 3.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,268,083 shares of the medical instr

Fisher Asset Management LLC decreased its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 17.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 711,667 shares of the medical instruments supplier's stock

Haemonetics Co. (NYSE:HAE - Get Free Report) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 3,260,000 shares, a growth of 30.4% from the May 15th total of 2,500,000 shares. Based on an average daily trading volume, of 536,400 shares, the days-to-cover ratio is presently 6.1 days. Approximately 6.5% of the company's shares are sold short.

Parkman Healthcare Partners LLC reduced its position in Haemonetics Co. (NYSE:HAE - Free Report) by 21.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,940 shares of the medical instruments supplier's

Needham & Company LLC upgraded Haemonetics from a "hold" rating to a "buy" rating and set a $112.00 price objective on the stock in a research report on Wednesday.

Haemonetics Co. (NYSE:HAE - Free Report) - Analysts at Zacks Research raised their Q1 2025 earnings estimates for Haemonetics in a research report issued to clients and investors on Tuesday, June 11th. Zacks Research analyst R. Department now expects that the medical instruments supplier will pos

Schroder Investment Management Group trimmed its position in Haemonetics Co. (NYSE:HAE - Free Report) by 14.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 656,810 shares of the

UBS Group AG increased its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 62.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 72,087 shares of the medical instruments supplier's stock after acquiring an additional 27,618 shares during the pe

Capital Research Global Investors lowered its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,523,568 shares of the medical instruments supplier's stock after selling 99,580 shares during

Campbell & CO Investment Adviser LLC bought a new stake in Haemonetics Co. (NYSE:HAE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 23,847 shares of the medical instruments supplier's stock

Shares of Haemonetics Co. (NYSE:HAE - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the four analysts that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating o

Norges Bank bought a new position in Haemonetics Co. (NYSE:HAE - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 334,357 shares of the medical instruments supplier's stock, valued at approximately $28,591,00

Isthmus Partners LLC acquired a new position in shares of Haemonetics Co. (NYSE:HAE - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 17,888 shares of the medical instrument

Haemonetics Co. (NYSE:HAE - Free Report) - Equities researchers at Zacks Research lifted their Q1 2025 earnings per share estimates for shares of Haemonetics in a research report issued to clients and investors on Friday, May 24th. Zacks Research analyst R. Department now anticipates that the med

Dimensional Fund Advisors LP boosted its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 826,731 shares of the medical instruments supplier's stock after bu

Westfield Capital Management Co. LP grew its position in Haemonetics Co. (NYSE:HAE - Free Report) by 27.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 712,061 shares of the medical instruments supplier's stock after buying an additional 152,098 shares du

Haemonetics (NYSE:HAE) Sees Strong Trading Volume

Haemonetics (NYSE:HAE) Shares Gap Down on Insider Selling

Dynamic Technology Lab Private Ltd acquired a new stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,385 shares of the medical instruments

Assenagon Asset Management S.A. acquired a new position in shares of Haemonetics Co. (NYSE:HAE - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,970 shares of the medical instruments

Haemonetics Co. (NYSE:HAE - Get Free Report) insider Stewart W. Strong sold 686 shares of the business's stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $95.11, for a total value of $65,245.46. Following the completion of the sale, the insider now directly owns 18,196 shares of the company's stock, valued at approximately $1,730,621.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Great Lakes Advisors LLC trimmed its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 14.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 169,255 shares of the medical instruments su

Jump Financial LLC bought a new position in Haemonetics Co. (NYSE:HAE - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 12,066 shares of the medical instruments supplier's stock, valued at approximately $1,032,000.

Haemonetics Co. (NYSE:HAE - Get Free Report) insider Stewart W. Strong sold 733 shares of the company's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the completion of the sale, the insider now directly owns 15,608 shares in the company, valued at $1,498,992.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Boston Partners lowered its position in Haemonetics Co. (NYSE:HAE - Free Report) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 707,434 shares of the medical instruments supplier's stock aft